| Weber, Thomas |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
| Recruiting | N/A | 1000 | Europe | | Medical University of Graz | Hypertrophic Cardiomyopathy | 03/44 | 03/44 | | |
TOGETHER, NCT06761235: Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients. |
|
|
| Not yet recruiting | N/A | 1246 | Europe | Standard BP intervention, Ambulatory blood pressure monitoring to diagnose hypertension and educational sessions to empower hypertensive patients, EVA intervention, Ambulatory blood pressure monitoring to diagnose hypertension plus estimated vascular age by brachial oscillometry and educational sessions to empower hypertensive patients | Enrique Rodilla, Health Research Fund of ISCIII Spain, AIT Austrian Institute of Technology GmbH, Institut et Haute Ecole de la Santé la Source, Instituto Politécnico de Coimbra, European Union | Hypertension and Cardiovascular Risk Factors | 11/26 | 12/26 | | |
| Greinert, Robin |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 124 | Europe | TIPS, Standard of Care, Terlipressin + Albumin | Jena University Hospital, German Research Foundation, University Hospital Halle (Saale) | Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic | 06/25 | 06/26 | | |
| Damm, Marko |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 124 | Europe | TIPS, Standard of Care, Terlipressin + Albumin | Jena University Hospital, German Research Foundation, University Hospital Halle (Saale) | Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic | 06/25 | 06/26 | | |
